MA58304B1 - Antagonistes du recepteur humain neonatal fc (fcrn) pour le traitement de troubles du pemphigus - Google Patents

Antagonistes du recepteur humain neonatal fc (fcrn) pour le traitement de troubles du pemphigus

Info

Publication number
MA58304B1
MA58304B1 MA58304A MA58304A MA58304B1 MA 58304 B1 MA58304 B1 MA 58304B1 MA 58304 A MA58304 A MA 58304A MA 58304 A MA58304 A MA 58304A MA 58304 B1 MA58304 B1 MA 58304B1
Authority
MA
Morocco
Prior art keywords
pemphigus
fcrn
antagonists
disorders
receptor
Prior art date
Application number
MA58304A
Other languages
English (en)
Inventor
Peter Verheesen
Patrick Dupuy
Original Assignee
argenx BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by argenx BV filed Critical argenx BV
Publication of MA58304B1 publication Critical patent/MA58304B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des méthodes de traitement du pemphigus à l'aide d'un antagoniste du FcRn tel que l'efgartigimod. Les méthodes selon l'invention permettent d'obtenir un délai d'action rapide pour permettre un contrôle précoce de la maladie et un entretien de la rémission clinique, avec ou sans dose minimale de corticostéroïdes.
MA58304A 2020-01-08 2021-01-08 Antagonistes du recepteur humain neonatal fc (fcrn) pour le traitement de troubles du pemphigus MA58304B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062958543P 2020-01-08 2020-01-08
US202062960647P 2020-01-13 2020-01-13
PCT/EP2021/050275 WO2021140202A1 (fr) 2020-01-08 2021-01-08 Méthodes de traitement de troubles du pemphigus
EP21701890.2A EP4087875B1 (fr) 2020-01-08 2021-01-08 Antagonistes du recepteur humain neonatal fc (fcrn) pour le traitement de troubles du pemphigus

Publications (1)

Publication Number Publication Date
MA58304B1 true MA58304B1 (fr) 2024-11-29

Family

ID=74285426

Family Applications (1)

Application Number Title Priority Date Filing Date
MA58304A MA58304B1 (fr) 2020-01-08 2021-01-08 Antagonistes du recepteur humain neonatal fc (fcrn) pour le traitement de troubles du pemphigus

Country Status (22)

Country Link
US (1) US12403175B2 (fr)
EP (2) EP4087875B1 (fr)
JP (1) JP2023509195A (fr)
KR (1) KR20220148804A (fr)
CN (1) CN115836086A (fr)
AU (1) AU2021206547A1 (fr)
BR (1) BR112022013554A2 (fr)
CA (1) CA3163172A1 (fr)
DK (1) DK4087875T3 (fr)
ES (1) ES2992247T3 (fr)
FI (1) FI4087875T3 (fr)
HU (1) HUE069311T2 (fr)
IL (1) IL294594A (fr)
LT (1) LT4087875T (fr)
MA (1) MA58304B1 (fr)
MD (1) MD4087875T2 (fr)
MX (1) MX2022008320A (fr)
PH (1) PH12022551646A1 (fr)
PL (1) PL4087875T3 (fr)
PT (1) PT4087875T (fr)
TW (1) TW202140552A (fr)
WO (1) WO2021140202A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12240875B2 (en) 2017-12-08 2025-03-04 argenx BV Use of FCRN antagonists for treatment of generalized myasthenia gravis
CA3101462A1 (fr) 2018-06-08 2019-12-12 Argenx Bvba Compositions et methodes de traitement de la thrombopenie immune
KR102921210B1 (ko) 2018-07-20 2026-01-30 모멘타 파머슈티컬스 인코포레이티드 Fcrn 항체 조성물
EP4007605A4 (fr) * 2019-08-01 2023-08-16 Momenta Pharmaceuticals, Inc. Anticorps anti-fcrn et leurs procédés d'utilisation
BR112022013554A2 (pt) 2020-01-08 2022-09-06 argenx BV Métodos para tratar distúrbios do pênfigo
WO2023012515A2 (fr) * 2021-08-02 2023-02-09 argenx BV Formes posologiques unitaires sous-cutanées
JP2025504815A (ja) * 2022-01-17 2025-02-19 アルジェニクス ビーブイ 自己抗体媒介性疾患を有する患者を治療するための方法
IL316524A (en) * 2022-04-26 2024-12-01 argenx BV Methods for treating bullous pemphigoid using FCRN antagonists
CA3258000A1 (fr) 2022-06-15 2023-12-21 argenx BV Molécules de liaison fcrn/antigène et procédés d'utilisation
KR20250109198A (ko) * 2022-11-14 2025-07-16 아르젠엑스 비브이 Fcrn 길항제 분자 및 이의 사용 방법

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62153300A (ja) 1985-12-26 1987-07-08 Teijin Ltd ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5326856A (en) 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
WO1993022332A2 (fr) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Production recombinante de domaines semblables a l'immunoglobuline dans des cellules procaryotes
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
EP1323346B1 (fr) 1995-01-17 2006-06-28 The Brigham And Women's Hospital, Inc. Transport épithélial spécifique de récepteurs d'immunogènes
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6992234B2 (en) 2000-11-06 2006-01-31 The Jackson Laboratory FcRn-based therapeutics for the treatment of auto-immune disorders
CA2467781C (fr) 2000-11-20 2014-09-23 Canadian Blood Services Utilisation d'un anticorps monoclonal dirige contre un globule rouge pour inhiber le systeme reticuloendothelial en vue de traiter la thrombocytopenie
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
EP2180044A1 (fr) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Variantes de glycosylation d'anticorps dotées de cytotoxicité cellulaire dépendante des anticorps améliorée
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP3945281B2 (ja) 2002-03-19 2007-07-18 富士ゼロックス株式会社 画像形成装置
DE60334453D1 (de) 2002-05-30 2010-11-18 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
EP1534335B9 (fr) 2002-08-14 2016-01-13 Macrogenics, Inc. Anticorps specifiques du recepteur fcgammariib et procedes d'utilisation de ces anticorps
WO2004029207A2 (fr) 2002-09-27 2004-04-08 Xencor Inc. Variants fc optimises et methodes destinees a leur generation
DE60334141D1 (de) 2002-10-15 2010-10-21 Facet Biotech Corp VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
EP1588166A4 (fr) 2003-01-09 2007-06-27 Macrogenics Inc Systeme vectoriel a double expression servant a exprimer des anticorps dans des cellules bacteriennes et mammiferes
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
WO2004062619A2 (fr) 2003-01-13 2004-07-29 Macrogenics, Inc. Proteines de fusion fc$g(g)r solubles et leurs procedes d'utilisation
RU2358763C2 (ru) 2003-02-10 2009-06-20 Элан Фармасьютикалз, Инк. Композиции иммуноглобулина и способ их получения
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
EP1789446A2 (fr) 2004-09-02 2007-05-30 Genentech, Inc. Molecules heteromultimeriques
WO2006035600A1 (fr) 2004-09-30 2006-04-06 Brother Kogyo Kabushiki Kaisha Appareil de communication d’étiquette sans fil, étiquette sans fil, système de communication d’étiquette sans fil et méthode de communication sans fil
BRPI0606867A2 (pt) 2005-01-28 2009-07-21 Wyeth Corp formulação lìquida; forma de dosagem unitária farmacêutica; kit; recipiente; método para aumentar a estabilidade de um polipeptìdeo de ligação a antìgeno numa formulação; método para preparar uma forma de dosagem unitária farmacêutica; formulação estável; formulação; e produto terapêutico
CA2606378A1 (fr) 2005-04-29 2006-11-09 The Jackson Laboratory Anticorops de fcrn et utilisations
WO2006122787A1 (fr) 2005-05-18 2006-11-23 Ablynx Nv Proteines de liaison a l'albumine serique
WO2006130834A2 (fr) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System Molecules d'immunoglobuline ayant des proprietes ameliorees
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
EP2144930A1 (fr) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Fc à chaîne simple, procédés de fabrication et procédés de traitement
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
CN101835802B (zh) 2007-06-01 2014-04-09 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
US8108517B2 (en) 2007-11-27 2012-01-31 Umber Systems System and method for collecting, reporting and analyzing data on application-level activity and other user information on a mobile data network
US20110059091A1 (en) 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
BRPI0910622A2 (pt) 2008-04-25 2020-03-10 Dyax Corp. ANTICORPOS CONTRA FcRn E USOS DOS MESMOS
WO2010014909A1 (fr) 2008-08-01 2010-02-04 Syntonix Pharmaceuticals, Inc. Peptides immunomodulateurs
EP2233500A1 (fr) 2009-03-20 2010-09-29 LFB Biotechnologies Variantes Fc optimisées
MY173526A (en) 2009-03-25 2020-01-31 Genentech Inc Novel anti-?5?1 antibodies and uses thereof
MX2012003282A (es) 2009-09-17 2012-04-30 Baxter Healthcare Sa Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
WO2011044368A1 (fr) 2009-10-07 2011-04-14 Macrogenics, Inc. Polypeptides contenant une région fc qui présentent une fonction d'effecteur améliorée due à des modifications de l'étendue de la fucosylation, et leurs méthodes d'utilisation
MX2012007676A (es) 2009-12-29 2012-08-03 Hoffmann La Roche Nueva formulacion de anticuerpo.
WO2012016073A2 (fr) 2010-07-28 2012-02-02 Gliknik Inc. Protéines de fusion de fragments de protéines humaines naturelles pour créer des compositions de fc d'immunoglobuline multimérisé de façon ordonnée
SG10201603962TA (en) 2011-05-25 2016-07-28 Innate Pharma Sa Anti-kir antibodies for the treatment of inflammatory disorders
KR102014554B1 (ko) 2011-06-02 2019-08-26 다이액스 코포레이션 Fc 수용체 결합 단백질
CN106046168A (zh) 2011-06-23 2016-10-26 埃博灵克斯股份有限公司 结合血清白蛋白的蛋白
GB201111291D0 (en) 2011-06-30 2011-08-17 Agco Int Gmbh Engine control system
CA2853637C (fr) 2011-10-26 2023-04-04 Novartis Ag Anticorps monoclonaux cd20 anticanins et methodes d'utilisation
EP2780463A4 (fr) 2011-11-18 2015-07-01 Merck Sharp & Dohme Polypeptides contenant fc ayant des propriétés anti-inflammatoires améliorées et une liaison améliorée à fcrn
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
US20150125449A1 (en) 2012-05-10 2015-05-07 Zymeworks Inc. Single-Arm Monovalent Antibody Constructs and Uses Thereof
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
DK3421486T5 (da) 2012-06-22 2024-09-16 The Trustees Of Darthmouth College Nye Vista-IG-konstruktioner og anvendelse af Vista-IG til behandling af autoimmune, allergiske og inflammatoriske lidelser
EP3578660A1 (fr) 2012-07-05 2019-12-11 F. Hoffmann-La Roche AG Système d'expression et de sécrétion
ES2660912T3 (es) 2013-03-15 2018-03-26 Affibody Ab Nuevos polipéptidos
KR101815265B1 (ko) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
WO2015065897A1 (fr) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Modèles de cancer et procédés associés
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
AU2014348552A1 (en) 2013-11-13 2016-06-02 Zymeworks Inc. Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
JP6620094B2 (ja) 2013-11-26 2019-12-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 免疫応答を調節するための組成物および方法
CN112142843B (zh) 2013-12-24 2024-10-18 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
SI3193930T1 (sl) 2014-09-17 2019-10-30 Affibody Ab Novi polipeptidi
KR20250052465A (ko) 2015-01-30 2025-04-18 모멘타 파머슈티컬스 인코포레이티드 ＦｃＲｎ 항체 및 이의 사용 방법
MY188761A (en) 2015-03-09 2021-12-29 Argenx Bvba Method of reducing serum levels of fc-containing agents using fcrn antagonists
ES2956662T3 (es) 2015-05-12 2023-12-26 Syntimmune Inc Anticuerpos anti-FcRn humanizados con afinidad madurada
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
JP7118884B2 (ja) 2015-07-17 2022-08-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物
CN106957365B (zh) 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
EP3448874A4 (fr) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Compositions pour le traitement de maladies
CA3032415A1 (fr) 2016-07-29 2018-02-01 Momenta Pharmaceuticals, Inc. Anticorps fcrn et leurs procedes d'utilisation
GB201618424D0 (en) 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
US12240875B2 (en) 2017-12-08 2025-03-04 argenx BV Use of FCRN antagonists for treatment of generalized myasthenia gravis
KR102904658B1 (ko) 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
CA3101462A1 (fr) 2018-06-08 2019-12-12 Argenx Bvba Compositions et methodes de traitement de la thrombopenie immune
EP3866785A1 (fr) 2018-10-15 2021-08-25 Merck Patent GmbH Polythérapie utilisant des agents d'alkylation d'adn et des inhibiteurs d'atr
US20220002402A1 (en) 2018-11-06 2022-01-06 Immunovant Sciences Gmbh Methods of treating graves' ophthalmopathy using anti-fcrn antibodies
GB2589049C (en) 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
WO2020227515A1 (fr) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions et méthodes d'augmentation vectorisée de la destruction, de l'expression et/ou de la régulation de protéines
WO2020236695A1 (fr) 2019-05-17 2020-11-26 Alexion Pharmaceuticals, Inc. Utilisation d'anticorps anti-fcrn dans le traitement du pemphighus et de maladies du pemphigoïde
CN114126647A (zh) 2019-06-07 2022-03-01 阿尔金克斯有限公司 适用于皮下施用的FcRn抑制剂的药物制剂
EP4007605A4 (fr) 2019-08-01 2023-08-16 Momenta Pharmaceuticals, Inc. Anticorps anti-fcrn et leurs procédés d'utilisation
BR112022013554A2 (pt) 2020-01-08 2022-09-06 argenx BV Métodos para tratar distúrbios do pênfigo
BR112022021392A2 (pt) 2020-04-22 2022-12-06 Igm Biosciences Inc Moléculas de ligação multiméricas de agonista de pd-1
IL302516A (en) 2020-11-06 2023-07-01 Janssen Biotech Inc FCRN antibodies and methods of using them
WO2023012515A2 (fr) 2021-08-02 2023-02-09 argenx BV Formes posologiques unitaires sous-cutanées
JP2025504815A (ja) 2022-01-17 2025-02-19 アルジェニクス ビーブイ 自己抗体媒介性疾患を有する患者を治療するための方法
KR20240151809A (ko) 2022-02-21 2024-10-18 아르젠엑스 비브이 Fcrn 길항제를 사용하여 근염을 치료하는 방법
IL316524A (en) 2022-04-26 2024-12-01 argenx BV Methods for treating bullous pemphigoid using FCRN antagonists
US20230407243A1 (en) 2022-06-15 2023-12-21 University Of Guelph Genetic platform to investigate the functions of bacterial drug efflux pumps
CA3258000A1 (fr) 2022-06-15 2023-12-21 argenx BV Molécules de liaison fcrn/antigène et procédés d'utilisation
WO2024052358A1 (fr) 2022-09-06 2024-03-14 Immunovant Sciences Gmbh Méthodes de traitement d'une polyneuropathie démyélinisante inflammatoire chronique à l'aide d'anticorps anti-fcrn
TW202428303A (zh) 2022-11-07 2024-07-16 比利時商阿根思公司 使用ｆｃｒｎ拮抗劑治療原發性膜性腎病變之方法
EP4615481A1 (fr) 2022-11-07 2025-09-17 argenx BV Méthodes de traitement de la néphropathie lupique à l'aide d'antagonistes de fcrn
KR20250109198A (ko) 2022-11-14 2025-07-16 아르젠엑스 비브이 Fcrn 길항제 분자 및 이의 사용 방법
AR131560A1 (es) 2023-01-06 2025-04-09 argenx BV Métodos para tratar pots mediante el uso de antagonistas de fcrn
IL322008A (en) 2023-01-12 2025-09-01 argenx BV Methods for treating primary Sjögren's syndrome with an FCRN antagonist
WO2024189430A1 (fr) 2023-03-14 2024-09-19 argenx BV Méthodes de vaccination d'un sujet traité avec un antagoniste de fcrn
CN121843716A (zh) 2023-07-16 2026-04-10 阿根思有限公司 用于治疗慢性炎性脱髓鞘性多发性神经病的方法
EP4530295A3 (fr) 2023-09-07 2025-05-28 argenx BV Antagonistes du fcrn et procédés d'utilisation

Also Published As

Publication number Publication date
AU2021206547A1 (en) 2022-07-14
FI4087875T3 (fi) 2024-10-25
KR20220148804A (ko) 2022-11-07
EP4454711A3 (fr) 2025-01-08
MD4087875T2 (ro) 2025-02-28
ES2992247T3 (es) 2024-12-11
PL4087875T3 (pl) 2025-01-20
CA3163172A1 (fr) 2021-07-15
US20210236596A1 (en) 2021-08-05
BR112022013554A2 (pt) 2022-09-06
CN115836086A (zh) 2023-03-21
PT4087875T (pt) 2024-10-29
EP4454711A2 (fr) 2024-10-30
HUE069311T2 (hu) 2025-02-28
PH12022551646A1 (en) 2024-02-12
AU2021206547A9 (en) 2023-06-29
MX2022008320A (es) 2022-10-21
DK4087875T3 (da) 2024-10-28
US12403175B2 (en) 2025-09-02
LT4087875T (lt) 2024-10-25
EP4087875B1 (fr) 2024-08-28
TW202140552A (zh) 2021-11-01
IL294594A (en) 2022-09-01
EP4087875A1 (fr) 2022-11-16
WO2021140202A1 (fr) 2021-07-15
JP2023509195A (ja) 2023-03-07

Similar Documents

Publication Publication Date Title
MA58304B1 (fr) Antagonistes du recepteur humain neonatal fc (fcrn) pour le traitement de troubles du pemphigus
Kanner Most antidepressant drugs are safe for patients with epilepsy at therapeutic doses: a review of the evidence
Raychaudhuri et al. Management of psoriatic arthritis: early diagnosis, monitoring of disease severity and cutting edge therapies
Rush et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study
Hirschfeld et al. Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination
Kuwabara et al. Different electrophysiological profiles and treatment response in ‘typical’and ‘atypical’chronic inflammatory demyelinating polyneuropathy
Feeney et al. Norepinephrine and brain damage: alpha noradrenergic pharmacology alters functional recovery after cortical trauma.
Goadsby Current concepts of the pathophysiology of migraine
Raskind Diagnosis and treatment of depression comorbid with neurologic disorders
MA58049B1 (fr) Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations
Jin et al. Exploring the potential of vagus nerve stimulation in treating brain diseases: a review of immunologic benefits and neuroprotective efficacy
Wójcik-Gryciuk et al. Glaucoma–state of the art and perspectives on treatment
Major et al. Massage-like stroking boosts the immune system in mice
Delpont et al. Clinical features of pain in amyotrophic lateral sclerosis: a clinical challenge
Hu et al. Navβ2 knockdown improves cognition in APP/PS1 mice by partially inhibiting seizures and APP amyloid processing
MA56998B1 (fr) Traitement de symptômes induits par le cycle menstruel
Perez et al. A combined therapeutic approach in stroke rehabilitation: a review on non-invasive brain stimulation plus pharmacotherapy
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine
Markiewicz et al. Brain-derived neurotrophic factor and matrix metalloproteinase-9 activity during rehabilitation therapy of schizophrenic patients–environmental pilot study
Riddle et al. A controlled trial of fluvoxamine for OCD in children and adolescents
EP3893890A4 (fr) Ginsénoside m1 utilisé en tant que modulateur d'enzymes de régulation de l'angiotensine et son utilisation pour le traitement de maladies ou d'états comprenant des symptômes provoqués par un coronavirus
Nevzorova Anxiety in patients with hyperthyroidism
Ekegren et al. 791 Incidence, costs and outcomes of non-union, delayed union and mal-union following long bone fracture
Albino Sociodemographic and clinical profile of patients attending psychiatry ambulatory services at the Quelimane general hospital, Mozambique
Doody Dimebon as a potential therapy for Alzheimer's disease